EIB Invests €20M in BioLamina to Accelerate Cell Therapies and Animal-Free Drug Testing

In a strategic move to strengthen Europe's leadership in biotechnology and regenerative medicine, the European Investment Bank (EIB) has announced a €20 million venture debt financing agreement with Swedish biotech firm BioLamina. The funding will support the large-scale development of cutting-edge laminin technologies—key to enabling next-generation cell therapies and transforming drug safety testing.

The investment comes at a pivotal moment for the global life sciences sector, as cell-based therapies rapidly transition from experimental research to clinical application. These therapies hold the potential to treat or even cure complex diseases such as type 1 diabetes, Parkinson's disease, heart failure, acute liver failure, and multiple forms of cancer—conditions that continue to pose significant treatment challenges worldwide.

Scaling a Critical Technology for the Future of Medicine

BioLamina's core innovation lies in its proprietary laminins—highly specialized proteins that replicate the natural environment in which human cells grow. These proteins serve as a biological "scaffold," enabling cells to develop, multiply, and function reliably in laboratory settings.

By providing a consistent and animal-free platform for cell cultivation, BioLamina's technology addresses one of the biggest bottlenecks in regenerative medicine: the ability to produce high-quality, reproducible cell lines at scale.

With EIB backing, the Stockholm-based company will:

• Expand and scale up production of laminins to meet growing global demand

• Optimize manufacturing processes for greater efficiency and consistency

• Broaden its product portfolio to support diverse therapeutic applications

• Strengthen its research and technological capabilities

BioLamina's products are already widely used by academic institutions, biotechnology firms, and major pharmaceutical companies, positioning the company as a critical enabler in the global biotech ecosystem.

Driving the Shift Toward Animal-Free Drug Testing

In addition to advancing cell therapies, the project is expected to accelerate the transition away from animal testing in drug development—a major ethical and scientific priority.

Traditional animal-based testing methods often fail to accurately predict human responses, leading to costly late-stage failures in drug development. BioLamina's human cell-based platforms offer a more reliable and scalable alternative, improving both the safety and efficiency of pharmaceutical research.

Industry analysts estimate that improved preclinical testing methods could save billions in drug development costs while significantly shortening time-to-market for new therapies.

A Strategic Investment in Europe's Innovation Economy

The financing is backed by the European Union's InvestEU programme and aligns with broader EU strategies such as TechEU and BioTechEU, which aim to position Europe as a global leader in high-impact innovation sectors.

EIB Vice-President Karl Nehammer emphasized the importance of scaling homegrown scientific breakthroughs into globally competitive enterprises.

"Europe needs to turn scientific excellence into global companies," Nehammer said. "By supporting BioLamina's growth, we are helping ensure that cutting-edge innovation in life sciences can scale in Europe, creating jobs, strengthening competitiveness and ultimately improving public health."

The funding is structured as venture debt—a form of long-term financing tailored for high-growth companies. Unlike traditional equity investment, venture debt allows companies to expand operations without immediate dilution of shareholder value, while extending their financial runway.

Addressing a Key Bottleneck in Cell Therapy Development

Despite rapid scientific advances, large-scale production of consistent, high-quality cells remains one of the biggest hurdles in bringing cell therapies to market.

BioLamina CEO Klaus Langhoff-Roos highlighted how the EIB investment will help overcome this challenge.

"Cell therapies are rapidly moving from scientific promise to clinical reality, but scaling the production of high-quality cell products remains a fundamental challenge," he said. "This financing allows us to expand our technology and manufacturing capabilities at a critical time."

By improving scalability and reproducibility, BioLamina's solutions could significantly accelerate the commercialization of regenerative treatments—bringing life-saving therapies closer to patients.

Strengthening Europe's Position in the Global Biotech Race

The global biotechnology market is projected to surpass $1 trillion in value over the coming decade, driven by advances in genomics, personalized medicine, and cell-based therapies. In this increasingly competitive landscape, Europe is seeking to close the gap with the United States and Asia by investing in high-potential companies and technologies.

The EIB's support for BioLamina reflects a broader shift toward strategic financing of innovation-driven enterprises that can deliver both economic and societal returns.

By enabling the scale-up of foundational technologies like laminins, the investment not only strengthens Europe's biotech capabilities but also contributes to a more resilient, future-ready healthcare system.

As demand for advanced therapies continues to grow, BioLamina's expansion could play a crucial role in shaping the next generation of medicine—where treatments are more precise, scalable, and effective.